RegulationPriority Review (United States), Accelerated Approval (United States), Orphan Drug (United States), PRIME (European Union), Regenerative Medicine Advanced Therapy (United States)

Structure/Sequence

Sequence Code 1277314924

Source: *****

Clinical Trials associated with Afamitresgene Autoleucel

NCT05642455

/ RecruitingPhase 1/2

A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.

Start Date01 Sep 2023

Sponsor / Collaborator-

NCT04408898

/ WithdrawnPhase 2

A Phase 2 Pilot Study of ADP-A2M4 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Cancer

This is a study to investigate the efficacy and safety of ADP-A2M4 in combination with pembrolizumab in HLA-A*02 eligible and MAGE-A4 positive subjects with recurrent or metastatic Head and Neck cancer.

Start Date02 Jul 2020

Sponsor / Collaborator

Adaptimmune Ltd.

NCT04044768

/ Active, not recruitingPhase 2

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .

Start Date13 Aug 2019

Sponsor / Collaborator-

100 Clinical Results associated with Afamitresgene Autoleucel

100 Translational Medicine associated with Afamitresgene Autoleucel

100 Patents (Medical) associated with Afamitresgene Autoleucel

Literatures (Medical) associated with Afamitresgene Autoleucel

31 Dec 2026·Human Vaccines & Immunotherapeutics

The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions

Review

Author: Keung, Emily ; Wannaphut, Chalothorn ; Roland, Christina ; Conley, Anthony ; Somaiah, Neeta ; Thirasastr, Prapassorn ; Araujo, Dejka ; Livingston, John

Cellular therapies representa promising area of immunotherapy for advanced cancers,therapies including T cell receptor (TCR) therapies, chimeric antigen receptor (CAR) T cell therapies, tumor-infiltrating lymphocyte (TIL) therapies, and natural killer (NK) cell therapies.Sarcomas pose unique challenges due to their molecular complexity and immunosuppressive tumor microenvironment (TME). TCRtherapiesargeting antigens likeNY-ESO-1, MAGE-A4, and PRAME have shown efficacy, highlighted by the FDA's accelerated approval of afamitresgene autoleucel targeting MAGE-A4 for synovial sarcoma.CAR-T cell therapies targeting HER2, GD2, and B7-H3, along with TIL, and NK cell therapies are also under investigation.However, many are in early stages of clinical development, and their effectiveness may vary by sarcoma subtype. Overcoming challenges such as immunosuppressive TME, antigen escape, lack of T-cell persistence, and off-target toxicities is crucial to improving outcomes for sarcoma patients. This review summarizes the evolution of cellular therapies,ongoing research, challenges, and future directions in this field.

03 Jun 2026·Expert Review of Anticancer Therapy

An evaluation of afamitresgene autoleucel for the treatment of advanced synovial sarcoma and myxoid round cell liposarcoma

Review

Author: Brahmi, Mehdi ; Dufresne, Armelle ; Romeo, Clémence ; Dupont, Margaux ; Blay, Jean Yves

INTRODUCTION:

Synovial sarcoma (SyS) and myxoid round-cell liposarcoma (MRCL) are rare, aggressive soft tissue sarcomas with poor outcomes at the advanced and metastatic stage. Novel therapeutic strategies are urgently needed. Afamitresgene autoleucel (afami-cel) is the first Food and Drug Administration (FDA)-approved, affinity-enhanced T-cell receptor (TCR) therapy targeting the cancer-testis antigen MAGE-A4 in HLA-A*02-positive patients.

AREAS COVERED:

This review summarizes clinical evidence from one early-phase study and the pivotal phase 2 SPEARHEAD-1 trial. Afami-cel achieved objective response rates of 39% in SyS and 25% in MRCL, with durable responses exceeding 11 months in SyS. The safety profile is manageable, with hematological toxicities from lymphodepletion and predominantly low-grade cytokine release syndrome; no treatment-related deaths occurred in SPEARHEAD-1.

EXPERT OPINION:

Afami-cel represents a milestone in sarcoma therapy, establishing proof of concept for engineered TCR T-cell therapies in solid tumors. However, challenges remain regarding HLA restriction, tumor microenvironment resistance, manufacturing delays and cost. Future efforts should focus on broadening applicability, optimizing combinations, and ensuring equitable access.

01 May 2026·Lancet Regional Health-Europe

Advances in cell therapy for solid tumours: European perspective and future directions

Review

Author: Haanen, John B A G ; Tak, Willemijn S ; Thistlethwaite, Fiona ; Yarza, Ramón ; Lim, Kok Haw Jonathan ; Moreno, Victor

Cell therapy has revolutionised the landscape of cancer treatment, with therapies such as Chimeric Antigen Receptor T cells (CAR-T cells), showing remarkable efficacy in haematological malignancies, and approaches such as Tumour Infiltrating Lymphocytes (TILs) and T-cell receptor-engineered T cells (TCR-T) showing increasing promise in solid tumours. The recent US FDA approvals of lifileucel (a TIL therapy for advanced melanoma) and afamitresgene autoleucel (a TCR therapy targeting MAGE-A4 in synovial sarcoma) mark the first regulatory recognition of cell therapies for solid tumours and signal a new era for oncology. Europe has played a central role in these advances, leading pivotal phase 3 trials and pioneering hospital-exemption-based manufacturing programmes. However, the continent still faces major challenges, including fragmented regulatory frameworks, high manufacturing costs, and inequitable patient access across member states. Emerging innovations such as gene-edited, allogeneic, and iPSC-derived cell products promise to address current limitations by improving scalability, safety, and time-to-treatment. This Series paper examines the latest advancements in cell therapy, focussing on the European experience, while comparing global trends. We discuss challenges specific to Europe, such as regulatory frameworks, manufacturing scalability, and disparities in access. Emphasis is placed on emerging innovations like gene-edited and allogeneic therapies, as well as future directions for integrating cell therapies into mainstream oncology. We conclude with recommendations for overcoming barriers related to cost, toxicity management, and equitable access across Europe.

News (Medical) associated with Afamitresgene Autoleucel

22 Jun 2026

·www.prnewswire.com

US WorldMeds® Receives Full U.S. FDA Approval of TECELRA® (afamitresgene autoleucel) with an Expanded Indication, Extending the First Approved Engineered T-Cell Therapy for a Solid Tumor to Children as Young as 12

Eligibility extends to patients with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and meet HLA and MAGE-A4 eligibility criteria LOUISVILLE, Ky., June 22, 2026 /PRNewswire/ -- USWM CT, LLC (US WorldMeds) announced that the U.S. Food and Drug Administration (FDA) has granted full approval of TECELRA® (afamitresgene autoleucel) and expanded its indication to include pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. Administered as a single infusion, TECELRA became the first engineered T-cell therapy for a solid tumor cancer to receive accelerated FDA approval in the United States, granted in August 2024. "Today's approval marks an important milestone not only for US WorldMeds, but for the synovial sarcoma community," said Breck Jones Sr., Founder and CEO of US WorldMeds. "With the transition to full approval, TECELRA continues to represent an important treatment option for appropriate patients with biomarker-eligible, advanced synovial sarcoma. This approval is supported by additional clinical evidence which may provide physicians, patients, and families with confidence as they consider treatment decisions. The expansion to include patients as young as 12 years old further broadens access to this personalized approach." "What sets TECELRA apart is that it is personalized to each individual, engineering a patient's own T-cells to detect, target, and attack their cancer. Until today, that option was only available to adults," said Kristen Gullo, Senior Vice President of US WorldMeds. "For patients 12 years of age and older with biomarker-eligible, advanced synovial sarcoma, today's decision opens the door to a new treatment approach that was previously out of reach and offers hope where options have been extremely limited." The full FDA approval and expanded indication for TECELRA was based on results of the SPEARHEAD-1 study (Cohorts 1, 2 and 3), an open-label, single-arm clinical study, which included 137 patients. The primary efficacy outcome was overall response rate (ORR) determined by independent review and supported by duration of response. TECELRA treatment resulted in an ORR of 43.8% with a complete response rate of 3.6%. The median duration of response was 5.3 months (95% CI: 4.5, 8.2). Among patients who were responsive to the treatment, 31.9% had a duration of response of 24 months or longer.* "For children as young as 12 with advanced synovial sarcoma, treatment options have been limited and navigating care decisions can be challenging," said Amy Armstrong, MD, Associate Professor of Pediatrics at Washington University School of Medicine in St. Louis and Director of the Solid Tumor Program at Siteman Kids at St. Louis Children's Hospital. "The availability of an engineered cell therapy for adolescents introduces an important new option for patients who are biomarker-eligible, allowing us to incorporate this approach into treatment planning based on the same evidence that has guided adult care. This is a meaningful step forward for the field." For more information about TECELRA visit . About Synovial Sarcoma There are more than 50 different types of soft tissue sarcomas which can arise in fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.1 Synovial sarcoma accounts for approximately 5 to 10% of all soft tissue sarcomas (there are approximately 13,400 new soft tissue sarcoma cases in the U.S. each year).1,2 Approximately one-third of patients with synovial sarcoma are diagnosed under the age of 30.2 The five-year survival rate for people with metastatic disease is approximately 20% and recurrence is common in advanced disease.1,3 About TECELRA TECELRA (afamitresgene autoleucel) is a genetically modified autologous T cell immunotherapy indicated for adult and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A02:01P, -A02:02P, -A02:03P, or -A02:06P positive, and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices . TECELRA is made from a patient's own white blood cells that are genetically modified to recognize and attack cancer cells. A healthcare provider will perform tests to see if TECELRA is right for each patient. IMPORTANT SAFETY INFORMATION Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA. After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 2 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 2 weeks after you get TECELRA. Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule. Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner. The most common side effects of TECELRA include nausea, fatigue, infection, fever (100.4°F/38°C or higher), constipation, vomiting, headache, diarrhea, fast heart rate, cough, increased aspartate aminotransferase, increased alanine aminotransferase, decreased lymphocyte count, decreased white blood cell count, decreased neutrophil count, decreased red blood cell count, and decreased platelet count. You are encouraged to report side effects to the FDA at (800) FDA-1088 or or to US WorldMeds at 1-855-246-9232. Please see full Prescribing Information, including Boxed Warning and Medication Guide . About US WorldMeds US WorldMeds is a U.S.-based pharmaceutical company focused on rare and specialty treatments. Our portfolio includes approved therapies for rare diseases and bleeding disorders, including IWILFIN®, REVONTO®, and TECELRA®. References 1 "What is a Soft Tissue Sarcoma?" American Cancer Society. . Accessed May 15, 2026. 2 "Soft Tissue Sarcoma." Cleveland Clinic. . Accessed May 15, 2026. 3 Jami SA, Mobarak SA, Jiandang S, et al. Clinical and strategic outcomes of metastatic synovial sarcoma on limb. Int J Health Sci(Qassim). 2020;14:38–43. *Per Kaplan-Meier method Media Contact Maria Lopes VP, Marketing & Commercial Operations USWM CT, LLC Phone: 1-833-935-6676 Email: [email protected] SOURCE US WorldMeds 21% more press release views with Request a Demo

Clinical ResultCell TherapyDrug ApprovalImmunotherapyAccelerated Approval

22 Jun 2026

·allsci.com

Tecelra converts to full US FDA approval, extends use to patients aged 12 and older

Louisville, Kentucky-based US WorldMeds has received full US FDA approval for Tecelra (afamitresgene autoleucel), the TCR-T cell therapy originally developed by Adaptimmune and acquired by US WorldMeds in 2025. The FDA gave the nod to convert the therapy’s August 2024 accelerated approval and expand its label to include pediatric patients as young as 12 years old with unresectable or metastatic synovial sarcoma. The decision is notable on two counts: it converts the first engineered T-cell therapy ever approved for a solid tumor from accelerated to full status, and it extends that access to adolescents — a population in which synovial sarcoma disproportionately occurs and for which systemic options have been limited. Tecelra is indicated for patients who have received prior chemotherapy, carry specific HLA alleles (HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P), and whose tumors express the MAGE-A4 antigen confirmed by an FDA-approved or cleared companion diagnostic. Administered as a single infusion, the therapy requires inpatient monitoring for at least seven days post-infusion, with patients advised to remain near a healthcare facility for two weeks. A boxed warning is included in the prescribing information. The full approval was supported by data from SPEARHEAD-1 (Cohorts 1, 2, and 3), an open-label, single-arm Phase II study enrolling 137 patients. The primary efficacy outcome was overall response rate (ORR) as determined by independent review. Tecelra demonstrated an ORR of 43.8%, with a complete response rate of 3.6%. Median duration of response was 5.3 months (95% CI: 4.5–8.2), and 31.9% of responding patients maintained a response for 24 months or longer. Tecelra is a genetically modified autologous T-cell therapy engineered to express an affinity-enhanced T-cell receptor (TCR) targeting MAGE-A4, a cancer-testis antigen expressed in synovial sarcoma but largely absent from normal adult tissue. Unlike CAR-T approaches, which recognize surface proteins, the TCR-based mechanism allows targeting of intracellular antigens presented via HLA molecules — the basis for the companion HLA-typing requirement. In the absence of a dedicated approved systemic therapy for synovial sarcoma specifically, the practical comparators in the post-chemotherapy setting are agents approved for broader soft tissue sarcoma populations. Pazopanib (Votrient), approved by the FDA in 2012 for previously treated advanced soft tissue sarcoma, and trabectedin (Yondelis), approved in 2015 for liposarcoma and leiomyosarcoma, are both used in this patient population — neither carries a synovial sarcoma-specific label, and neither is biomarker-restricted. Tecelra’s eligibility criteria, while narrowing the treatable population, define a molecularly selected group in which the 43.8% ORR represents a clinically meaningful signal relative to available alternatives. US WorldMeds acquired Tecelra and the broader Adaptimmune cell-therapy portfolio in August 2025 for USD 55 million upfront, with up to USD 30 million in additional milestone payments. The full approval and pediatric label expansion represent the first major regulatory milestone under that ownership. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Clinical ResultCell TherapyDrug ApprovalImmunotherapyAcquisition

12 May 2026

·www.biospace.com

Infinitopes Appoints Immuno-Oncology Pioneer Jo Brewer as Chief Scientific Officer (CSO) to Advance Therapeutic Pipeline From Clinical to Commercialisation

Joining Infinitopes as CSO and interim COO, Jo Brewer, PhD, an innovator in the field of immunotherapy, will help sustainably scale the company on its journey through clinical development. Expansion of the executive leadership team supports the company’s ambition to grow its AI/ML-powered antigen discovery platform into a therapeutic pipeline. Move further strengthens clinical to commercial capability as Infinitopes steers its first vaccine candidate to prevent recurrence in oesophageal cancer through early investigational trial. OXFORD, England & BOSTON--(BUSINESS WIRE)--Infinitopes, a biotechnology company developing novel and precision immunotherapy, today announces the appointment of Jo Brewer, PhD, as Chief Scientific Officer and interim Chief Operating Officer. Dr. Brewer, a pioneer and recognised industry leader in cancer immunotherapy and cell therapies, has served as a non-executive director (NED) of the company since March 2025, now joining the executive leadership team at a key inflection point in the company’s growth. The appointment follows the start of the VISTA trial at the end of last year: a first-in-human, double-blind, randomised, placebo-controlled Phase I/IIa clinical trial of ITOP1, Infinitopes’ leading precision therapeutic vaccine, designed to prevent the recurrence of oesophageal cancer in the first line, neoadjuvant setting; an area where clinical need remains largely unmet. ITOP1 is a next-generation off-the-shelf cancer vaccine using the company's proprietary vector technology to induce potent T-cell responses in patients suffering from surgically resectable oesophageal adenocarcinoma (OAC). With 20 years of experience in advancing therapies from early-stage discovery to commercialisation, Dr. Brewer joins Infinitopes from Adaptimmune, where she was a founding scientist and served as CSO. Jo was instrumental in the development of Tecelra®, the first engineered TCR-T cell therapy for solid tumours to reach the market. Commenting on her new, permanent, role as CSO at Infinitopes, Jo said: " This is a really exciting moment in Infinitopes’ innovation journey, where cutting-edge science transitions from lab into the clinical realm. I have always been passionate about shepherding science from 'bench-to-bedside’ and am excited by the ITOP1 product development programme and its potential to revolutionise first line treatment for those living with cancer. "I am thrilled to join at this critical clinical stage in the company’s development. I’ll be tapping into the full breadth and depth of my experience to build on the critical work of the co-founders Jonathan Kwok, Senthil Chinnakannan and Lian Ni Lee, helping them to drive their vision to the next level.” Dan Menichella, a seasoned biotech executive who recently took up the position of interim CEO of Infinitopes from his role as NED, added: “Not only does Jo have hands-on experience successfully transitioning a candidate from concept to market, but she’s also adept at steering growth in scaling organisations in a sustainable way. We’re delighted to have her join us on a permanent basis at this point in our innovation journey.” Jo Brewer and Dan Menichella’s appointments enable co-founding CEO Dr Jonathan Kwok to transition to Infinitopes’ President & Chief Medical Officer, with a focus on guiding Infinitopes’ strategy and clinical development, leading execution of the VISTA trial and AI business technologies. Together these appointments will help drive the next exciting chapter in Infinitopes’ development story. In January this year, the company announced the successful extension of its seed financing round, securing an additional $15.4 million to bring the total raised to $35.1 million. About Jo Brewer Chief Scientific Officer & Interim Chief Operating Officer Jo Brewer, PhD, is a recognised industry leader in cancer immunotherapy and cell therapies, with over 20 years of experience bringing cutting-edge treatments from discovery to the clinic. As a founding scientist at Adaptimmune, Jo played a critical role in the development of multiple cell-based immunotherapies that led to partnerships with Genentech, Galapagos, Astellas and GSK. She has built and led multiple research teams and helped the company scale from a small biotech to 500+ employees, driving innovation across discovery and translational science. About Infinitopes Infinitopes Ltd is a clinical stage, integrated cancer biotechnology company supported by Cancer Research UK (CRUK) and the University of Oxford. The Company combines two world-leading platforms, in precision target discovery and in high-efficiency, vector delivery systems, to develop immunologically durable vaccines against multiple solid tumour indications. A Phase I/IIa trial of the lead vaccine candidate, ITOP1, began in Q4 2025, following UK Medicines and Healthcare products Regulatory Agency (MHRA) Clinical Trial Application (CTA) approval. Infinitopes has gathered in-house talent across antigen discovery, immunology, vaccinology, oncology, biomanufacturing, clinical trials and regulation, winning an 'Innovative Licensing and Access Pathway' (ILAP) innovation passport from the MHRA in 2022. Infinitopes has also won two prestigious, maximum size, nondilutive awards from Innovate UK, a Cancer Therapeutics Award (in 2022), and a Future Economy Investor Partnership (in 2023). Since incorporation, the Infinitopes team has raised over $35.1m from sector experts, including Amplify Bio, Cancer Research Horizons, Cancer Research Institute, Kindred Capital, Macmillan Cancer Support, Manta Ray Ventures, Martlet, Meltwind, Octopus Ventures, Saras Capital, Wilbe and the Fundación CRIS Contra el Cáncer, funding its rapid growth from three academic co-founders to a team of 20 full time equivalents. It is now the largest tenant of Oxford University's BioEscalator innovation accelerator. For more information, visit Contacts For further information please contact: Infinitopes Tom Weir Email: tom@infinitopes.com FINN Partners Jim Smith Tel: +44 7854 214426 Email: jim.smith@finnpartners.com

VaccineExecutive ChangeImmunotherapy

100 Deals associated with Afamitresgene Autoleucel

External Link

KEGG	Wiki	ATC	Drug Bank
D12951	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Synovial Sarcoma	United States	Adaptimmune LLC	02 Aug 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Esophageal Carcinoma	Phase 3	United Kingdom	Adaptimmune Ltd.	30 Jan 2022
Myxoid Liposarcoma	Phase 3	United Kingdom	Adaptimmune Ltd.	30 Jan 2022
Ovarian Cancer	Phase 3	United Kingdom	Adaptimmune Ltd.	30 Jan 2022
Stomach Cancer	Phase 2	Spain	-	31 Jul 2021
Squamous Cell Carcinoma of Head and Neck	Phase 2	United States	Adaptimmune Ltd.	02 Jul 2020
Malignant neoplasm of gastro-oesophageal junction	Phase 1	United Kingdom	Adaptimmune Ltd.	30 Jan 2022
Bladder Cancer	Phase 1	United States	-	15 May 2017
Bladder Cancer	Phase 1	Canada	-	15 May 2017
MAGEA4-Positive Solid tumor	Phase 1	United States	-	15 May 2017
MAGEA4-Positive Solid tumor	Phase 1	Canada	-	15 May 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04044768 (ASCO2026)	Phase 1/2	Synovial Sarcoma HLA-A*02 positive \| MAGE-A4 positive	153	Afamitresgene autoleucel (afami-cel) (HLA-A*02 positive + MAGE-A4 positive + metastatic synovial sarcoma)	jdqqbmqqsj(beepinaicv) = npipxhysce uazkjsjono (uqhlmarvgx, 4.7 - 10.6) View more	Positive	29 May 2026
NCT04044768 (SPEARHEAD-1, FDA_CBER) Manual	Phase 2	Synovial Sarcoma HLA-A02:01P \| HLA-A02:02P \| HLA-A*02:03P ... View more	44	TECELRA	lemxkzrqtx(lzdzpjmlyf) = ofvyzgaqvz ormpihgbbv (frngtqqhfg, 28.4 - 59.0) View more	Positive	02 Aug 2024
NCT04044768 (SPEARHEAD-1, Literature \| Pubmed \| Lancet) Manual	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma	52	Afamitresgene autoleucel	zkduwqpwqg(uyhfwhgkww) = pinotpgwlj panzclaogd (phywcotiho, 24–51) View more	Positive	27 Mar 2024
	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma	52	Afamitresgene autoleucel (synovial sarcoma)	zkduwqpwqg(uyhfwhgkww) = wnjpuxgqrd panzclaogd (phywcotiho, 24–55)	Positive	27 Mar 2024
NCT04044768 (SPEARHEAD-1, ESMO_SRC2024) Manual	Phase 2	Synovial Sarcoma \| Myxoid Liposarcoma	52	Afamitresgene autoleucel	fwbpxrxgsp(rtebhqjwld) = czddxfihug mpyrmizyiu (gnwxoaxmxb ) View more	Positive	14 Mar 2024
NCT04044768 \| NCT03132922 (SPEARHEAD-1, Biospace) Manual	Not Applicable	Synovial Sarcoma	-	Afami cel	qrhmzodjec(hyycbnfddj) = itbtaeuvzb fgpqkjdvdp (csflgbioca ) View more	Positive	06 Dec 2023
NCT04044768 (SPEARHEAD-1, ASCO 12023 \| ASCO 22023) Manual	Phase 2	Synovial Sarcoma	44	Afamitresgene Autoleucel (Cohort 1)	ecqemibnpv(lfqotlhfgh) = knxtjddcmn llnkmzclhc (zkqwmlftek, 2.8 - 5.8) View more	Positive	31 May 2023
NCT04044768 (SPEARHEAD-1, ASCO 12023 \| ASCO 22023) Manual	Phase 2	Synovial Sarcoma	72	Afamitresgene Autoleucel	rrggbaxmeh(pagcjkujcm) = uglndyrotg jkswokfehe (vpwguylacf ) View more	Positive	26 May 2023
NCT03132922 (SPEARHEAD-1, ASGCT2023)	Phase 1	MAGE-A4	-	Afami-cel	qkcqyoyegv(uvczrwvlid) = ioubeuabzj uatcjsfkdd (dkuoikpxzc ) View more	Positive	01 May 2023
NCT03132922 (Pubmed \| Nat Med) Manual	Phase 1	MAGEA4-Positive Solid tumor \| Ovarian Cancer \| Synovial Sarcoma ... HLA-A*0201 Positive \| MAGEA4 Positive View more	38	Afamitresgene autoleucel	ospknhgjpy(xescegvgcs) = All patients (N = 38, nine tumor types) experienced Grade ≥3 hematologic toxicities; 55% of patients (90% Grade ≤2) experienced cytokine release syndrome. eelzlodjnb (hagbcahjki )	Positive	01 Jan 2023
NCT03132922 (Pubmed \| Nat Med) Manual	Phase 1		38	Afamitresgene autoleucel (synovial sarcoma)		Positive	01 Jan 2023
NCT04044768 \| NCT03132922 (SPEARHEAD-1, ASCO2022)	Phase 1/2	Synovial Sarcoma \| Myxoid Liposarcoma HLA-A*02+ \| MAGE-A4+	69	Afami-cel	dikofmbrty(fcrgbdyacz) = xsvgxezljj jtbxjgrfkw (nvwffrfrlx ) View more	-	02 Jun 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis